Items Tagged ‘ALK gene’

June 12th, 2017

Alecensa Superior to Xalkori in Treatment of Lung Cancer

By

Alecensa (alectinib) halted the spread of lung cancer for a median of 15 months longer than treatment with rival Xalkori (crizotinib) with fewer side effects, according to trial results presented at the 2017 American Society of Clinical Oncology annual meeting in Chicago. Both drugs are designed to treat advanced non-small cell lung cancer (NSCLC) in […]

View full entry

Tags: Alecensa, alectinib, ALK gene, ALK-positive NSCLC, crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, precision medicine, xalkori